| New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER(Qsymia). | Cardiol Rev | 2014 Jan-Feb | 24304809 |
| The efficacy of a low dose combination of topiramate and naltrexone on ethanolreinforcement and consumption in rat models. | Pharmacol Biochem Behav | 2014 Jan | 24252444 |
| Pharmacotherapy of alcohol use disorders: seventy-five years of progress. | J Stud Alcohol Drugs Suppl | 2014 | 24565314 |
| New pharmacological treatments for the management of obesity. | Curr Gastroenterol Rep | 2014 | 24828101 |
| Drug treatment of obesity in the cardiovascular patient. | Curr Opin Cardiol | 2013 Sep | 23928924 |
| A review of the metabolic effects of controlled-release Phentermine/Topiramate. | Hormones (Athens) | 2013 Oct-Dec | 24457398 |
| Obesity consults--comprehensive obesity management in 2013: understanding theshifting paradigm. | Obesity (Silver Spring) | 2013 Nov | 24259347 |
| Update on treatment of essential tremor. | Curr Treat Options Neurol | 2013 Aug | 23881742 |
| Determination of topiramate in human plasma using liquid chromatography tandemmass spectrometry. | Acta Chim Slov | 2013 | 23841344 |
| Topiramate treatment improves hypothalamic insulin and leptin signaling andaction and reduces obesity in mice. | Endocrinology | 2012 Sep | 22822160 |